Description: Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on developing oncology therapeutics with a pipeline designed with a range of oncology products in China. The company develops oncology drug candidates, including antibody-drug conjugates (ADC), oncolytic virus drugs, and immunotherapies. It develops immuno-oncology products, such as HX008 Anti-PD-1 mAb and LP002 Anti-PD-L1 mAb; ADC products, including MRG003 EGFR-targeted ADC, MRG002 HER2-targeted ADC, MRG001 CD20-targeted ADC, MRG004A TF-targeted ADC, and CMG901 CLDNI8.2-targeted ADC; CG0070 oncolytic virus; and other drug candidates, such as HX008+OH2, LP002+OH2, and HX008+LP002. The company was incorporated in 2018 and is headquartered in Shanghai, China.
Home Page: www.lepubiopharma.com
Building 41
Shanghai,
201612
China
Phone:
86 21 6769 6099
Officers
| Name | Title |
|---|---|
| Dr. Zhongjie Pu | Exec. Chairman |
| Dr. Ziye Sui M.D., Ph.D. | CEO & Director |
| Dr. Chaohong Hu | Co-CEO & Director |
| Ms. Yunyi Li | CFO & Board Sec. |
| Dr. Minmin Qin Ph.D. | CTO & Sr. VP |
| Ms. Siu Kuen Lai FCIS, FCS | Joint Company Sec. |
Exchange: HK
Country: HK
Currency: Hong Kong Dollar (HK$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 11.0342 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 371 |